NO20065191L - Fremgangsmate for fremstilling av dipeptidyl IV inhibitorer og mellomprodukter derav - Google Patents

Fremgangsmate for fremstilling av dipeptidyl IV inhibitorer og mellomprodukter derav

Info

Publication number
NO20065191L
NO20065191L NO20065191A NO20065191A NO20065191L NO 20065191 L NO20065191 L NO 20065191L NO 20065191 A NO20065191 A NO 20065191A NO 20065191 A NO20065191 A NO 20065191A NO 20065191 L NO20065191 L NO 20065191L
Authority
NO
Norway
Prior art keywords
acid
inhibitors
dipeptidyl
boc protected
intermediates
Prior art date
Application number
NO20065191A
Other languages
English (en)
Norwegian (no)
Inventor
Michael Politino
Matthew M Cadin
Paul M Skonezny
Jason G Chen
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO20065191L publication Critical patent/NO20065191L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/06—Lysis of microorganisms
    • C12N1/066—Lysis of microorganisms by physical processes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0008—Oxidoreductases (1.) acting on the aldehyde or oxo group of donors (1.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0014—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4)
    • C12N9/0016—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4) with NAD or NADP as acceptor (1.4.1)
    • C12N9/0018—Phenylalanine dehydrogenase (1.4.1.20)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/04—Alpha- or beta- amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/04—Alpha- or beta- amino acids
    • C12P13/22—Tryptophan; Tyrosine; Phenylalanine; 3,4-Dihydroxyphenylalanine
    • C12P13/222—Phenylalanine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P15/00—Preparation of compounds containing at least three condensed carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/10—Nitrogen as only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
    • C12Y102/02—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with a cytochrome as acceptor (1.2.2)
    • C12Y102/02001—Formate dehydrogenase (cytochrome) (1.2.2.1)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20065191A 2004-04-14 2006-11-13 Fremgangsmate for fremstilling av dipeptidyl IV inhibitorer og mellomprodukter derav NO20065191L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56198604P 2004-04-14 2004-04-14
PCT/US2005/012615 WO2005106011A2 (fr) 2004-04-14 2005-04-13 Procede de preparation d'inhibiteurs de la dipeptidyl peptidase iv et de leurs intermediaires

Publications (1)

Publication Number Publication Date
NO20065191L true NO20065191L (no) 2006-11-13

Family

ID=35242266

Family Applications (3)

Application Number Title Priority Date Filing Date
NO20065191A NO20065191L (no) 2004-04-14 2006-11-13 Fremgangsmate for fremstilling av dipeptidyl IV inhibitorer og mellomprodukter derav
NO20151145A NO20151145L (no) 2004-04-14 2015-09-07 Fremgangsmåte for fremstilling av dipeptidyl IV inhibitorer og mellomprodukter derav
NO20151146A NO20151146L (no) 2004-04-14 2015-09-07 Fremgangsmåte for fremstilling av dipeptidyl IV inhibitorer og mellomprodukter derav

Family Applications After (2)

Application Number Title Priority Date Filing Date
NO20151145A NO20151145L (no) 2004-04-14 2015-09-07 Fremgangsmåte for fremstilling av dipeptidyl IV inhibitorer og mellomprodukter derav
NO20151146A NO20151146L (no) 2004-04-14 2015-09-07 Fremgangsmåte for fremstilling av dipeptidyl IV inhibitorer og mellomprodukter derav

Country Status (16)

Country Link
US (4) US7741082B2 (fr)
EP (3) EP1737970A4 (fr)
JP (3) JP4896872B2 (fr)
KR (1) KR101269813B1 (fr)
CN (3) CN1968925B (fr)
AR (1) AR048695A1 (fr)
AU (1) AU2005238442A1 (fr)
BR (1) BRPI0509890A (fr)
CA (1) CA2563903A1 (fr)
IL (1) IL178520A0 (fr)
NO (3) NO20065191L (fr)
PE (1) PE20060255A1 (fr)
RU (1) RU2373194C2 (fr)
TW (1) TW200540274A (fr)
WO (1) WO2005106011A2 (fr)
ZA (1) ZA200608304B (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7420079B2 (en) * 2002-12-09 2008-09-02 Bristol-Myers Squibb Company Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof
US7741082B2 (en) 2004-04-14 2010-06-22 Bristol-Myers Squibb Company Process for preparing dipeptidyl peptidase IV inhibitors and intermediates therefor
WO2007085933A2 (fr) * 2006-01-25 2007-08-02 Glenmark Pharmaceuticals Limited Procede de preparation d’un complexe n-[1-(s)-ethoxycarbonyl-1-butyl]-(s)-alanine-dmt et son utilisation dans la preparation du perindopril
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
PE20090696A1 (es) 2007-04-20 2009-06-20 Bristol Myers Squibb Co Formas cristalinas de saxagliptina y procesos para preparar las mismas
PE20090938A1 (es) 2007-08-16 2009-08-08 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
EP2146210A1 (fr) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Procédés d'utilisation du récepteur couplé aux protéines A G pour identifier les secrétagogues de peptide YY (PYY) et composés utiles dans le traitement d'états modulés par PYY
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
MX370599B (es) 2008-08-15 2019-12-18 Boehringer Ingelheim Int Derivados de purina para su uso en el tratamiento de enfermedades relacionadas con fab.
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
TWI466672B (zh) 2009-01-29 2015-01-01 Boehringer Ingelheim Int 小兒科病人糖尿病之治療
PL2395983T3 (pl) 2009-02-13 2020-09-07 Boehringer Ingelheim International Gmbh Kompozycja farmaceutyczna zawierająca inhibitor sglt2, inhibitor dpp-iv i ewentualnie dalszy środek przeciwcukrzycowy oraz jej zastosowania
NZ619520A (en) 2009-02-13 2015-06-26 Boehringer Ingelheim Int Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
US8158394B2 (en) 2009-04-08 2012-04-17 Bristol-Myers Squibb Company Genetically stable plasmid expressing PDH and FDH enzymes
MY145258A (en) * 2009-07-06 2012-01-11 Univ Sains Malaysia A system for producing l-homophenylalanine and a process for producing l-homophenylalanine
NZ599298A (en) 2009-11-27 2014-11-28 Boehringer Ingelheim Int Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
FR2956400A1 (fr) 2010-02-15 2011-08-19 Finorga Procede de preparation de composes adamantyles
EP2547339A1 (fr) 2010-03-18 2013-01-23 Boehringer Ingelheim International GmbH Combinaisons d'agonistes de gpr119 et d'inhibiteurs de dpp-iv, linagliptine, pour le traitement du diabète et d'états apparentés
EA201291169A1 (ru) 2010-05-05 2013-04-30 Ассия Кемикал Индастриз Лтд. Промежуточные соединения саксаглиптина, полиморфы саксаглиптина и способы их получения
WO2011138421A1 (fr) 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combinaison thérapeutique
NZ603319A (en) 2010-06-24 2015-04-24 Boehringer Ingelheim Int Diabetes therapy
WO2012028721A1 (fr) 2010-09-03 2012-03-08 Sandoz Ag Procédé d'amination réductrice d'acides α-céto-carboxyliques
US8410288B2 (en) 2010-10-04 2013-04-02 Teva Pharmaceutical Industries Ltd. Polymorphs of Saxagliptin hydrochloride and processes for preparing them
US9125729B2 (en) * 2011-10-21 2015-09-08 Aquatic Therapy Innovations, Llc Buoyancy-based cervical traction system
WO2013081100A1 (fr) * 2011-11-30 2013-06-06 積水メディカル株式会社 Composé adamantyl hydantoïne
WO2013174767A1 (fr) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh Dérivé de xanthine en tant qu'inhibiteur de la dpp-4 à utiliser dans la modification de l'apport alimentaire et dans la régulation des préférences alimentaires
EP2867206A2 (fr) 2012-07-02 2015-05-06 Ranbaxy Laboratories Limited Sels de saxagliptine
CN103539724B (zh) * 2012-07-12 2017-09-26 博瑞生物医药（苏州）股份有限公司 沙格列汀单一立体异构体的新晶型和纯化方法
WO2014108830A1 (fr) 2013-01-10 2014-07-17 Wockhardt Limited Procédé pour la préparation de sel pharmaceutiquement acceptable de saxagliptine
CN103265473A (zh) * 2013-06-04 2013-08-28 上海同昌生物医药科技有限公司 一种生产沙格列汀的方法
ITMI20131029A1 (it) * 2013-06-20 2014-12-21 Chemelectiva S R L Intermedi utili per la preparazione di saxagliptina
CN103555683B (zh) * 2013-11-19 2015-11-18 南京博优康远生物医药科技有限公司 一种沙格列汀手性中间体的合成方法
WO2015087262A1 (fr) 2013-12-11 2015-06-18 Ranbaxy Laboratories Limited Procédé pour la préparation de saxagliptine et de ses intermédiaires
CN103724254A (zh) * 2013-12-23 2014-04-16 上海应用技术学院 一种沙克列汀中间体的制备方法
CN105315189A (zh) * 2014-05-29 2016-02-10 上海医药工业研究院 一种制备（5s）-5-氨基羰基-4,5-二氢-1h-吡咯-1-羧酸-1（1,1-二甲基乙基）酯的方法
CN104098505A (zh) * 2014-07-31 2014-10-15 天津民祥生物医药科技有限公司 一种沙格列汀的制备方法
CN104177284B (zh) * 2014-08-01 2016-08-24 常州大学 合成3-氮杂二环[3,1,0]己基-1-甲醛的方法
CN104293844B (zh) * 2014-08-26 2017-10-10 苏州永健生物医药有限公司 一种特拉匹韦中间体的合成方法
CN104356046B (zh) * 2014-11-02 2017-04-05 浙江医药高等专科学校 环烷基取代的环己烷羧酸酰胺类衍生物及其用途
CN104356048B (zh) * 2014-11-02 2016-08-24 浙江医药高等专科学校 环己烷羧酸酰胺类衍生物、其制备方法和用途
HK1249847A1 (zh) 2015-03-09 2018-11-16 Intekrin Therapeutics, Inc. 用於治疗非酒精性脂肪肝疾病和/或脂肪营养不良的方法
CN105130879B (zh) * 2015-07-24 2018-03-02 沧州那瑞化学科技有限公司 （R）‑3‑Boc‑氨基哌啶的制备方法
CN106554301B (zh) * 2015-09-30 2018-09-21 深圳翰宇药业股份有限公司 一种沙格列汀关键中间体的制备方法
CN106755152B (zh) * 2017-01-23 2020-06-16 苏州引航生物科技有限公司 一种制备奥格列汀中间体的方法
KR20200036808A (ko) 2017-04-03 2020-04-07 코히러스 바이오사이언시스, 인크. 진행성 핵상 마비 치료를 위한 PPARγ 작용제
CN109970620B (zh) * 2017-12-27 2022-07-12 江苏威凯尔医药科技有限公司 一种制备沙格列汀中间体的方法
RU2712097C1 (ru) * 2018-09-28 2020-01-24 Общество с ограниченной ответственностью "Необиотек" Ингибитор дипептидилпептидазы-4 для лечения сахарного диабета 2-го типа, соединения (варианты)
CN112391363B (zh) * 2021-01-21 2021-04-06 凯莱英生命科学技术(天津)有限公司 氨基酸脱氢酶突变体及其应用
CN119039583B (zh) * 2024-11-01 2025-03-11 浙江农林大学 一种具有立构复合结晶性能侧链碱基生物可降解聚酯酰胺及其酶促制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1023896A (ja) * 1996-05-07 1998-01-27 Unitika Ltd 組換えプラスミド、それにより形質転換された大腸菌、その培養物及びそれを用いたアミノ酸又はその誘導体の製造方法
IL120873A0 (en) 1996-05-24 1997-09-30 Tanabe Seiyaku Co Process for preparing optically active 2-halogen-3-hydroxypropionic acid ester
US6068991A (en) 1997-12-16 2000-05-30 Bristol-Myers Squibb Company High expression Escherichia coli expression vector
EP1097236A4 (fr) 1998-07-15 2006-10-04 Bristol Myers Squibb Co Amination reductrice stereoselective de cetones
CO5150173A1 (es) * 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
US6395767B2 (en) * 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
AU8069801A (en) 2000-08-16 2002-02-25 Bristol Myers Squibb Co Stereoselective reduction of substituted oxo-butanes
US6828119B2 (en) 2001-01-04 2004-12-07 Bristol Myers Squibb Company Enzymatic deprotection of amines and hydroxides
EP1383886B1 (fr) * 2001-04-03 2008-07-30 Bristol-Myers Squibb Company D-hydantoinase d'ochrobactrum anthropi
WO2003054155A2 (fr) * 2001-12-19 2003-07-03 Bristol-Myers Squibb Company Pichia pastoris formate deshydrogenase et ses utilisations
US7420079B2 (en) 2002-12-09 2008-09-02 Bristol-Myers Squibb Company Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof
TW200538122A (en) 2004-03-31 2005-12-01 Bristol Myers Squibb Co Process for preparing a dipeptidyl peptidase Ⅳ inhibitor and intermediates employed therein
US7741082B2 (en) 2004-04-14 2010-06-22 Bristol-Myers Squibb Company Process for preparing dipeptidyl peptidase IV inhibitors and intermediates therefor
TW200536827A (en) 2004-05-04 2005-11-16 Bristol Myers Squibb Co Enzymatic ammonolysis process for the preparation of intermediates for DPP IV inhibitors
US7214702B2 (en) 2004-05-25 2007-05-08 Bristol-Myers Squibb Company Process for producing a dipeptidyl peptidase IV inhibitor

Also Published As

Publication number Publication date
WO2005106011A2 (fr) 2005-11-10
US8222009B2 (en) 2012-07-17
CA2563903A1 (fr) 2005-11-10
EP2894227A2 (fr) 2015-07-15
US20050260712A1 (en) 2005-11-24
US8361761B2 (en) 2013-01-29
NO20151145L (no) 2006-11-13
WO2005106011A3 (fr) 2006-10-26
EP1737970A4 (fr) 2011-08-24
BRPI0509890A (pt) 2007-10-30
RU2373194C2 (ru) 2009-11-20
US20130204012A1 (en) 2013-08-08
JP2007532137A (ja) 2007-11-15
KR101269813B1 (ko) 2013-05-30
EP3000893A3 (fr) 2016-06-29
RU2006140134A (ru) 2008-05-27
US8809024B2 (en) 2014-08-19
CN103215321B (zh) 2015-09-09
CN1968925A (zh) 2007-05-23
AR048695A1 (es) 2006-05-17
JP2011177177A (ja) 2011-09-15
EP3000893A2 (fr) 2016-03-30
JP2013121351A (ja) 2013-06-20
TW200540274A (en) 2005-12-16
CN1968925B (zh) 2013-04-17
CN103215320B (zh) 2015-09-23
JP4896872B2 (ja) 2012-03-14
US20100291642A1 (en) 2010-11-18
IL178520A0 (en) 2007-02-11
AU2005238442A1 (en) 2005-11-10
JP5715169B2 (ja) 2015-05-07
CN103215321A (zh) 2013-07-24
US7741082B2 (en) 2010-06-22
PE20060255A1 (es) 2006-03-31
KR20070006903A (ko) 2007-01-11
EP1737970A2 (fr) 2007-01-03
JP5210406B2 (ja) 2013-06-12
EP2894227A3 (fr) 2015-08-12
US20120276600A1 (en) 2012-11-01
ZA200608304B (en) 2008-07-30
CN103215320A (zh) 2013-07-24
NO20151146L (no) 2006-11-13

Similar Documents

Publication Publication Date Title
WO2005106011A3 (fr) Procede de preparation d'inhibiteurs de la dipeptidyl peptidase iv et de leurs intermediaires
NO20071866L (no) Prosesser for beskyttelse av optisk aktive aminderivater
IL173802A0 (en) Adamantane and azabicyclo-octane and nonane derivatives, process of their preparation and their use as dpp-iv inhibitors
WO2008013997A3 (fr) Substrats fluorescents de transporteurs de monoamines en tant que faux neurotransmetteurs optiques
PL372799A1 (en) New compounds
EP2123636A4 (fr) Procédé de préparation d'un dérivé d'aminoacétylpyrrolidinecarbonitrile
TW201129553A (en) Dipeptidyl peptidase inhibitors
MY141797A (en) Biochemical synthesis of 6-amino caproic acid
WO2004085661A3 (fr) Procede de synthese de derives d'acides amines beta chiraux
NO923533L (no) Nye 5-amino-4-hydroksyheksansyrederivater som terapeutika
MX2009002740A (es) Inhibidores de renina.
SG169983A1 (en) Aspartic protease inhibitors
TW200604150A (en) Method for producing (meth)acrylate derivative having isocyanate group
TW200618796A (en) Ammonolysis process for the preparation of intermediates for DPP IV inhibitors
IL187640A0 (en) Method for preparing clopidogrel and intermediates used therein
DK1761478T3 (da) En isoleret Atomoxetin urenhed, fremgangsmåde til fremstilling af Atomoxetin urenheder og deres anvendelse som referencestandarder
PE20060307A1 (es) Proceso de amonolisis enzimatica para preparacion de compuestos intermediarios para inhibidores de dipeptidilo peptidasa iv
DK0904348T3 (da) Fremgangsmåde til fremstilling af aminoalkoholer og derivater deraf
IL186014A (en) Process for the preparation of 2-azabicyclo[3.3.0] octane-3-carboxylic acid derivatives
TW200718688A (en) Fluorinated ryridine N-oxide thrombin modulators and process for N-oxidation of nitrogen containing heteroaryls
TW200719889A (en) Amino acid derivatives
WO2003080855A3 (fr) Deracemisation d'amines
PL1667987T3 (pl) Sposób wytwarzania mykofenolanu mofetylu
DK0992495T3 (da) Fremgangsmåde til opnåelse af quinaprilhydrochlorid og solvater, der er nyttige ved isolation og rensning af quinaprilhydrochlorid
EP2189450A4 (fr) Procédé de fabrication d'un dérivé de quinazoline

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: ASTRAZENECA AB, SE

FC2A Withdrawal, rejection or dismissal of laid open patent application